Category - Developments

Developments

Kane Biotech retains GR Consulting to seek partnerships for DispersinB wound care hydrogel

Kane Biotech (TSXV:KNE) retained GR Consulting to develop and implement an out-licensing strategy for its DispersinB wound care hydrogel for both the U.S. and European markets. “Gary and Edwin have years of experience...

October 31, 2019

Developments

REGENXBIO exercises option on Clearside’s SCS Microinjector

REGENXBIO (NASDAQ:RGNX) exercised its option to license Clearside Biomedical’s (NASDAQ:CLSD) in-office, SCS Microinjector for the delivery of adeno-associated virus (AAV)-based therapeutics. The agreement includes, but...

October 30, 2019

Developments

Biostage submits IND for Cellspan esophageal implant

Biostage (OTCQB:BSTG) filed an IND with the FDA for its Cellspan esophageal implant (CEI). According to Biostage, patients who require surgical treatment for esophageal disease have complication rates of more than 50%...

October 30, 2019

Developments

Surmodics gets FDA breakthrough device designation for sirolimus-coated balloon

Surmodics (NASDAQ:SRDX) received FDA breakthrough device designation for its sirolimus-coated balloon (SCB), called Sundance, for the treatment of critical limb ischemia (CLI) and below-the-knee arterial disease. CLI...

October 29, 2019

Developments

TG Therapeutics umbralisib meets primary endpoint in Phase 2b lymphoma trial

TG Therapeutics (NASDAQ:TGTX) reported the follicular lymphoma (FL) cohort of the its Phase 2b pivotal trial of umbralisib met the primary endpoint of overall response rate (ORR). The trial included 188 FL patients who...

October 29, 2019

Developments

Liminal BioSciences to present PAH data at AHA meeting

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) plans to present two scientific posters with new preclinical development in the treatment of pulmonary arterial hypertension (PAH) at the American Heart Association annual...

October 29, 2019

Developments

IVERIC bio Zimura meets primary endpoint in Phase 2b dry AMD trial

Based on initial topline data, IVERIC bio’s (NASDAQ:ISEE) Zimura met its prespecified primary endpoint in a Phase 2b dry age-related macular degeneration (AMD) clinical trial. IVERIC’s Phase 2b trial assessed Zumira, a...

October 28, 2019

Developments

Chardan Healthcare completes merger with BiomX

Chardan Healthcare Acquisition (NYSE:CHAC), a special purpose acquisition company sponsored by affiliates of Chardan Capital Markets, closed its merger with BiomX Ltd., a microbiome company developing both natural and...

October 28, 2019

Developments

MacroGenics doses first patient in Phase 2/3 gastroesophageal cancer trial

MacroGenics (NASDAQ:MGNX) dosed the first patient in its Phase 2/3 MAHOGANY clinical trial of margetuximab for the treatment of HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The trial will...

October 25, 2019

Developments

Fresenius gets FDA breakthrough device designation for hemodialysis system

Fresenius Medical Care (NYSE:FMS) received FDA breakthrough device designation for its hemodialysis system, which is being developed for the prevention of blood clotting without the use of blood thinner medication. Many...

October 24, 2019

Category - Developments

Kane Biotech retains GR Consulting to seek partnerships for DispersinB wound care hydrogel

REGENXBIO exercises option on Clearside’s SCS Microinjector

Biostage submits IND for Cellspan esophageal implant

Surmodics gets FDA breakthrough device designation for sirolimus-coated balloon

TG Therapeutics umbralisib meets primary endpoint in Phase 2b lymphoma trial

Liminal BioSciences to present PAH data at AHA meeting

IVERIC bio Zimura meets primary endpoint in Phase 2b dry AMD trial

Chardan Healthcare completes merger with BiomX

MacroGenics doses first patient in Phase 2/3 gastroesophageal cancer trial

Fresenius gets FDA breakthrough device designation for hemodialysis system

General

More